Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00999401 | A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 103 | — | — | Apr 1, 2009 | Aug 13, 2019 | Dec 22, 2021 | 2 | United States |
MTD of both sapacitabine and seliciclib administered sequentially in advanced solid tumor patients
| Arm | Type | Description |
|---|---|---|
| sapacitabine and seliciclib | EXPERIMENTAL | Sequential or concomitant administration of sapacitabine and seliciclib |
| Name | Type | Description |
|---|---|---|
| sapacitabine and seliciclib | DRUG | sequential or concomitant administration of sapacitabine and seliciclib |
Inclusion Criteria: * Incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists; at the RD of Part 1, an extension cohort up to 20 patients with metastatic breast cancer who are known to be BRCA mutation carriers will be enrolled....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |